KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Intangibles (2016 - 2025)

Biomarin Pharmaceutical's Intangibles history spans 17 years, with the latest figure at $213.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles fell 16.23% year-over-year to $213.8 million, compared with a TTM value of $213.8 million through Dec 2025, down 16.23%, and an annual FY2025 reading of $213.8 million, down 16.23% over the prior year.
  • Intangibles for Q4 2025 was $213.8 million at Biomarin Pharmaceutical, down from $233.1 million in the prior quarter.
  • The five-year high for Intangibles was $405.9 million in Q1 2021, with the low at $213.8 million in Q4 2025.
  • Average Intangibles over 5 years is $312.1 million, with a median of $306.4 million recorded in 2023.
  • Year-over-year, Intangibles soared 1160.57% in 2021 and then decreased 16.23% in 2025.
  • Tracing BMRN's Intangibles over 5 years: stood at $388.7 million in 2021, then fell by 12.89% to $338.6 million in 2022, then decreased by 12.96% to $294.7 million in 2023, then decreased by 13.38% to $255.3 million in 2024, then fell by 16.23% to $213.8 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Intangibles are $213.8 million (Q4 2025), $233.1 million (Q3 2025), and $239.6 million (Q2 2025).